JDRF and the Type 1 Diabetes Clinical Research Network (T1DCRN) are proud to congratulate Professor John Shine AO and Professor Peter Colman for receiving Queen’s Birthday Honours this month.
Professor John Shine, Head of the Neuronal Stem Cells Laboratory at Garvan Institute of Medical Research and Chairman of CSL Ltd. received a Companion in the General Division of the Order of Australia (AC).
He was recognised for eminent service to medical research, particularly in the area of biopharmaceuticals and molecular biology, to higher education as an academic, to professional medical organisations, and as a supporter of the advancement of innovation in science. JDRF is privileged to have him as a member of the Advisory Board.
His discoveries have revolutionised the entire medical industry with key advances in the field of DNA cloning and gene expression. Among many other achievements, he was a central figure in the cloning of the human insulin gene and was the first to demonstrate that hormone genes cloned in bacteria could be expressed in a biologically active form.
Mr Mike Wilson, CEO and Managing Director of JDRF Australia says “John is a leader in medical research and his work has revolutionised the entire medical industry. Our type 1 diabetes community have benefited directly from his work, with a breakthrough discovery allowing large-scale production of human insulin to treat the disease. JDRF is extremely grateful for his expert guidance on the Advisory Board, and we congratulate John on this well-deserved honour.”
Professor Peter Colman, Director of Diabetes and Endocrinology at Royal Melbourne Hospital, was awarded a Member in the General Division of the Order of Australia (AM).
Professor Colman was recognised for his significant service to medicine in the field of endocrinology, particularly diabetes research, patient education and clinical management.
Professor Colman is considered an expert in the global diabetes field and the T1DCRN is extremely fortunate to have him as Chair of the T1DCRN Steering Committee. His involvement with the T1DCRN extends even further, as a Principal investigator for the Australasian Diabetes Data Network (ADDN), and Co-Investigator on the adult hybrid closed loop trial and Environmental Determinants of Islet Autoimmunity (ENDIA) study.
Professor Colman’s major research interests centre on the prediction and prevention of type 1 diabetes as evidenced by his involvement in an international trial of a nasal vaccine which aims to prevent people from developing type 1 diabetes. Alongside A/Prof John Wentworth, Peter co-leads the Australian/New Zealand Type 1 TrialNet International Centre. TrialNet is an international collaborative network that aims to prevent, delay and reverse the progression of type 1 diabetes.
Dr Dorota Pawlak, Head of Research Development & Director of the T1DCRN said “Peter has been a leader in the diabetes field for many years. Peter is not only an exceptional researcher and clinician; he’s an exceptional role model. His passion to improve the care of those with diabetes has been the driving force behind his work as a teacher, mentor, clinician and researcher. JDRF and the type 1 diabetes community more broadly congratulate Peter on this well-deserved recognition”.